Who are the top shareholders of the Sai Life?

The top shareholders of Sai Life include Tpg Asia Vii Sf Pte Ltd with 24.73%, promoter Mytreyi Kanumuri at 10.64%, mutual funds holding 11.54%, and foreign institutional investors at 12.36%, while individual investors own 7.69%. A small portion of promoter holdings is pledged at 2.6741%.

The top shareholders of Sai Life include a mix of institutional and individual investors. The largest public shareholder is Tpg Asia Vii Sf Pte Ltd, holding 24.73%. Among the promoters, Mytreyi Kanumuri, a partner at Marigold Partners, has the highest stake at 10.64%. Additionally, mutual funds hold 11.54% of the shares through 21 schemes, while foreign institutional investors (FIIs) account for 12.36% with 73 FIIs involved. Individual investors collectively hold 7.69% of the company. The majority of the shareholding is held by non-institutional investors, with a small portion of promoter holdings being pledged at 2.6741%.

how big is Sai Life?

As of Jun 06, Sai Life Sciences Ltd has a market capitalization of 15,316.00 Cr, with recent net sales of 1,854.06 Cr and net profit of 239.76 Cr for the last four quarters. Shareholder's funds are valued at 975.14 Cr, and total assets amount to 2,262.00 Cr.

Market Cap: <BR>As of Jun 06, Sai Life Sciences Ltd has a market capitalization of 15,316.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest 4 quarters, the company reported a sum of Net Sales of 1,854.06 Cr and a sum of Net Profit of 239.76 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: <BR>The Balance Sheet data is also on a Consolidated basis for the reporting period ending Mar'24. Shareholder's Funds are valued at 975.14 Cr, while Total Assets amount to 2,262.00 Cr.

When is the next results date for Sai Life?

No Upcoming Board Meetings

Has Sai Life declared dividend?

No Dividend History Available

Is Sai Life overvalued or undervalued?

As of February 7, 2025, Sai Life is considered overvalued with a "very expensive" rating due to high valuation metrics like a PE ratio of 88.33 and an EV to EBITDA of 38.80, significantly exceeding its peers, despite recent stock performance outpacing the Sensex.

As of 7 February 2025, Sai Life has moved from a grade of "does not qualify" to "very expensive." The company is currently overvalued based on its high valuation metrics, including a PE ratio of 88.33, an EV to EBIT of 57.30, and an EV to EBITDA of 38.80. These figures significantly exceed those of its peers, such as Sun Pharmaceutical Industries Ltd., which has a PE ratio of 35.25 and an EV to EBITDA of 24.91, and Cipla Ltd., which boasts a much lower PE ratio of 22.99 and an EV to EBITDA of 15.93.<BR><BR>In comparison to its industry, Sai Life's valuation appears excessive, particularly when considering its PEG ratio of 0.00, indicating no growth expectations priced into the stock. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 4.16% compared to the Sensex's 1.35%, suggesting some investor optimism despite the high valuation. Overall, given the significant premium over its peers and the valuation grade, Sai Life is deemed overvalued.

Is Sai Life technically bullish or bearish?

As of June 23, 2025, the market trend is neutral with no strong signals, indicating a consolidation phase despite mildly bullish Bollinger Bands.

As of 23 June 2025, the technical trend has changed from mildly bullish to sideways. The current stance is neutral, with no strong bullish or bearish signals present. The MACD and KST indicators show no clear trend on both weekly and monthly time frames. The RSI is also indicating no signal on the weekly and monthly charts. While the Bollinger Bands are mildly bullish on the weekly, the overall lack of definitive trends in the moving averages, Dow Theory, and OBV suggests a consolidation phase. The recent price action, with a decline from the previous close, further supports this neutral outlook.

Who are the peers of the Sai Life?

Sai Life's peers include Alembic Pharma, Concord Biotech, Neuland Labs, Jubilant Pharmo, Natco Pharma, Blue Jet Health, Caplin Point Lab, Sanofi India, and Alivus Life, with varying management risk and growth ratings. Neuland Labs has the highest 1-year return at 69.64%, while Natco Pharma has the lowest at -20.35%.

Peers: The peers of Sai Life are Alembic Pharma, Concord Biotech, Neuland Labs., Jubilant Pharmo, Natco Pharma, Blue Jet Health, Caplin Point Lab, Sanofi India, and Alivus Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech and Sanofi India, while Good management risk is found at Alembic Pharma, Neuland Labs., Natco Pharma, Blue Jet Health, Caplin Point Lab, and Alivus Life, and Average management risk is noted at Jubilant Pharmo and Sai Life. Growth is rated as Excellent for Concord Biotech and Natco Pharma, Good for Sai Life, Neuland Labs., and Jubilant Pharmo, while Below Average growth is seen at Alembic Pharma, Blue Jet Health, and Alivus Life, and Average growth is noted at Caplin Point Lab. Capital Structure is Excellent for Concord Biotech, Neuland Labs., Natco Pharma, Blue Jet Health, Caplin Point Lab, and Alivus Life, while Good capital structure is observed at Sai Life and Average at Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Neuland Labs. at 69.64%, while Natco Pharma has the lowest at -20.35%. Sai Life's 1-year return is not available for comparison. Additionally, Natco Pharma and Sanofi India have negative six-month returns.

What does Sai Life do?

Sai Life Sciences Ltd is a mid-cap pharmaceutical and biotechnology company, reporting net sales of ₹5,795 Cr and a net profit of ₹883 Cr for the quarter ending March 2025, with a market cap of ₹16,888 Cr. The company has a P/E ratio of 98.00 and a return on equity of 8.00%.

Overview:<BR>Sai Life Sciences Ltd is a mid-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Sai Life Sciences Limited was incorporated in 1999 as 'Sai Dru Syn Laboratories Limited' and later changed its name in 2003. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 5,795 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 883 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 16,888 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 98.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.08 <BR>Return on Equity: 8.00% <BR>Price to Book: 7.81 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

How has been the historical performance of Sai Life?

Sai Life experienced significant financial growth from March 2024 to March 2025, with net sales rising to 1,694.57 Cr and profit after tax increasing to 170.13 Cr. The company improved its operating profit margin to 23.94% and reduced total debt from 710.16 Cr to 128.64 Cr.

Answer:<BR>The historical performance of Sai Life shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Sai Life's consolidated net sales increased from 1,465.18 Cr in March 2024 to 1,694.57 Cr in March 2025, reflecting a strong upward trend in total operating income as well. The company's total expenditure rose to 1,288.91 Cr from 1,179.69 Cr, with notable increases in raw material costs and employee costs. Operating profit (PBDIT) improved significantly, reaching 442.44 Cr, up from 314.58 Cr, while profit before tax also saw a substantial rise to 227.70 Cr from 109.23 Cr. Consequently, profit after tax surged to 170.13 Cr compared to 82.81 Cr the previous year. The operating profit margin increased to 23.94% from 19.48%, and the PAT margin improved to 10.04% from 5.65%. On the balance sheet, total assets grew to 3,145.78 Cr from 2,262.00 Cr, driven by increases in shareholder's funds and cash reserves, which rose to 463.88 Cr from 158.80 Cr. The company also reduced its total debt significantly from 710.16 Cr to 128.64 Cr. Overall, Sai Life demonstrated robust financial growth and improved profitability in the fiscal year ending March 2025.

Are Sai Life latest results good or bad?

Sai Life Sciences' latest Q2 FY26 results are strong, with a net profit of ₹83.84 crore, a 101.98% year-on-year increase, and revenue growth of 35.88% to ₹537.47 crore. Improved operating and PAT margins, along with reduced interest expenses, indicate effective cost management and a solid growth trajectory.

Sai Life Sciences' latest results for Q2 FY26 can be considered quite strong. The company reported a net profit of ₹83.84 crore, which reflects a remarkable year-on-year increase of 101.98%. Additionally, revenue grew by 35.88% compared to the same quarter last year, reaching ₹537.47 crore. This growth is a positive sign of improving operational performance and demand for their services.<BR><BR>Moreover, the operating margin improved to 27.13%, up 129 basis points from the previous year, and the PAT margin surged to 15.60%, marking a significant 511 basis points increase. These metrics indicate that the company is effectively managing its costs while enhancing profitability.<BR><BR>The reduction in interest expenses by 55.32% year-on-year also contributes positively to the bottom line, as the company has eliminated long-term debt, which enhances financial flexibility. Overall, the results demonstrate strong operational leverage and a solid growth trajectory, suggesting that Sai Life is performing well in its sector.

Should I buy, sell or hold Sai Life?

Which are the latest news on Sai Life?

Why is Sai Life falling/rising?

As of 04-Dec, the stock price of Sai Life Sciences Ltd is 868.80, down 0.35%. Despite a year-to-date gain of 15.65%, the stock has underperformed recently, with a 5.89% drop over the past month, contrasting with the Sensex's rise.

As of 04-Dec, the stock price of Sai Life Sciences Ltd is currently at 868.80, reflecting a decrease of 3.05 points or 0.35%. The stock has been underperforming, having fallen consecutively for the last two days, resulting in a total decline of 0.95% during this period. Additionally, over the past week, the stock has decreased by 0.71%, while the benchmark Sensex has only seen a slight decline of 0.53%. <BR><BR>In terms of longer-term performance, the stock has experienced a significant drop of 5.89% over the past month, contrasting sharply with the Sensex, which has risen by 2.16% in the same timeframe. Despite these short-term declines, the year-to-date performance remains positive, with a gain of 15.65%, outperforming the Sensex's 9.12% increase.<BR><BR>Today's trading activity indicates a rising investor participation, as evidenced by a delivery volume of 2.55 lacs on December 3, which represents a 125.31% increase compared to the five-day average. However, the stock's performance today has underperformed its sector by 0.64%. <BR><BR>While the company shows strong fundamentals, such as a low Debt to EBITDA ratio and healthy growth in operating profit and net profit, these positive factors have not translated into immediate stock price appreciation. The current market sentiment appears to be cautious, contributing to the stock's recent decline.